Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up on Analyst Upgrade

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped up prior to trading on Monday after China Intl Cap upgraded the stock to a strong-buy rating. The stock had previously closed at $26.28, but opened at $27.24. Ascentage Pharma Group International shares last traded at $27.6240, with a volume of 3,340 shares changing hands.

A number of other brokerages have also recently weighed in on AAPG. BTIG Research restated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Thursday, March 26th. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Finally, Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $48.00.

Institutional Trading of Ascentage Pharma Group International

A number of large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth about $96,000. ABC Arbitrage SA acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth about $204,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International during the third quarter worth about $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, XY Capital Ltd raised its position in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the last quarter.

Ascentage Pharma Group International Trading Down 4.1%

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The firm’s 50 day moving average is $24.01 and its 200-day moving average is $29.08.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million for the quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.